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Abstract  
 
The organization and mining of malaria genomic and post-genomic data is highly 
motivated by the necessity to predict and characterize new biological targets and new 
drugs. Biological targets are sought in a biological space designed from the genomic 
data from Plasmodium falciparum, but using also the millions of genomic data from 
other species. Drug candidates are sought in a chemical space containing the millions 
of small molecules stored in public and private chemolibraries. Data management 
should therefore be as reliable and versatile as possible. In this context, we examined 
five aspects of the organization and mining of malaria genomic and post-genomic 
data: 1) the comparison of protein sequences including compositionally atypical 
malaria sequences, 2) the high throughput reconstruction of molecular phylogenies, 3) 
the representation of biological processes particularly metabolic pathways, 4) the 
versatile methods to integrate genomic data, biological representations and functional 
profiling obtained from X-omic experiments after drug treatments and 5) the 
determination and prediction of protein structures and their molecular docking with 
drug candidate structures. Progresses toward a grid-enabled chemogenomic 
knowledge space are discussed.Text for this section of the abstract… 
 
Background  
Malaria is a life-threatening disease affecting half a billion humans in 
underdeveloped and developing countries. Its global heartland is Africa, with an 
appalling death toll of 1 to 2 million people every year [1]. Endemic malaria ranges 
from a permanent incidence in sub-Saharan and equatorial Africa, to a seasonal but 
recently escalating prevalence in Southern Africa [2]. Four species of malaria 
parasites can infect humans via mosquito transmission: Plasmodium falciparum (the 
species that causes the greatest incidence of illness and death) as well as P. vivax, P. 
ovale, and P. malariae. They belong to the Apicomplexa phylum, which contains 
thousands of other parasitic protists of medical and veterinary importance, including 
plasmodia that infect non-human vertebrates, and other genera, such as Toxoplasma, 
Neospora, Babesia, Cryptosporidium etc [3]. 
Malaria was eradicated from temperate regions following concerted 
preventative sanitary actions and after important insecticide campaigns and systematic 
treatments with available drugs, i.e. quinine and chloroquine [4-6]. The last 
indigenous case was reported in the Netherlands in 1961 [7]. Unfortunately, the 
prophylactic programs of the 1950's and 1960's, essentially based on insecticide and 
drug treatments, failed to control malaria in subtropical areas [8]. Resistance to 
chloroquine spread rapidly [9, 10]. Subsequent attempts to achieve progress in 
malaria prophylaxis have been characterized by the failure of vaccine development, 
withdrawal of some insecticides because of toxicity and negative environmental 
impact, the alarming spreading of mosquitoes' resistance to insecticides and of 
Plasmodium to the very few drugs that have been developed [10-12]. The promise of 
an effective vaccine is as distant as ever [13]. Current efforts focus on 
chemoprophylaxis using artemisinin, an antiplasmodial molecule from Artemisia 
annua, and derivatives which can be produced efficiently and cheaply. However the 
scientific community is worried that plans for the extensive use of artemisinin might 
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be ruined by emergence of the parasitic resistance it will almost certainly trigger, 
sooner or later [14, 15]. Given the small number of available drugs and the resistance 
they have already induced, discovery of new targets and of new drugs remains a key 
priority. 
A major landmark in the history of malaria was the launch of a collaborative 
genomic sequencing program in 1996 ([16, 17]; for review: [18-21]). In November 
2002, the complete genome of the 3D7 strain of P. falciparum [22] and a whole 
genome-shotgun of P. yoelii yoelii [23] were released, followed by whole-genome 
shotguns of P. berghei, P. chabaudi, and P. vivax, and genomic sequencing of P. 
gallinaceum, P. knowlesi and P. reichenowi which are still under progress [21, 24]. 
This unprecedented effort to sequence genomes of eukaryotic pathogens was a 
technical challenge, because the extreme compositional bias of Plasmodium DNA 
(>80% A+T in P. falciparum) accounted for the instability of genomic fragments in 
bacteria [17-19] and complicated assembly of contigs [19]. Among eukaryotes, the 
Plasmodium genus is therefore the best documented at the genomic sequence level, 
with well established syntenic relations.  At the level of the Apicomplexa phylum, 
additional complete genomes of Cryptosporidium, Theileria and Toxoplasma have 
been either released or announced [25-26].  
All Plasmodium molecular data have been collected and organized in the 
PlasmoDB public database as early as sequencing outputs were made available [27-
30]. The architecture of the relational database was designed following biologically 
relevant relationships, i.e. the "gene to mRNA to protein" dogma, using the 
Gemomics Unified Schema [28-29], and ensures that gene loci are linked to 
annotation using the Gene Ontology standards [30]. A genome browser allows 
navigation along chromosome sequences and the viewing of multiple Plasmodium 
species at one glance, based on syntenies. Predictions of protein domains, post-
translational modifications, subcellular targeting sequences, etc. are included. 
Furthermore, PlasmoDB is currently the only site where molecular data are (1) 
tentatively clustered based on homology, (2) linked to generic schemes designed to 
view metabolic pathways, and (3) linked to X-omic functional information 
(transcriptome, proteome, interactome): any biologist can exploit these integrated data 
with basic or combined queries [27-30]. It is therefore the first resource designed to 
help the scientific community to turn genomic data hopefully into gold, i.e. 
appropriate biological knowledge that can accelerate the design and introduction of 
new therapeutic strategies. PlasmoDB operates inside ApiDB, a master web portal for 
apicomplexan genomes [29, 32].  
Contrasting with this clever, integrated and user-friendly access to molecular 
and functional data, the proportion of genes for which a biological function has been 
inferred appears like a curse. Only 34 % of the P. falciparum genes could be assigned 
a function, based on detected sequence homology with characterized genes from other 
organisms [22, 33, 34]. The most-sequenced eukaryotic group appears therefore as the 
worst functionally annotated. The first version of the P. falciparum genome was 
estimated to code for 5268 proteins, out of which 3208 did not have any significant 
similarity to proteins in other organisms to justify provision of functional assignment. 
This proportion of uncharacterized genes was further increased by 257 additional 
sequences, which had significant similarity to proteins, described as hypothetical, in 
other organisms [22]. The 2005 updated EMBL version of the 3D7 complete genome 
(generated at Sanger Institute, The Institute for Genomic Research, and Stanford 
University; version 2.1) was still predicted to encode as many as 3548 hypothetical 
proteins (65.6 % of total). This figure is the worst ever recorded for a eukaryotic 
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genome (Table 1) and a clear limitation to any in silico exploration of the malaria 
biology.  
 
<Table 1> 
 
Since absence of evidence is not evidence of absence, the scientific 
community faces a serious epistemological problem when trying to derive conclusions 
from a small genome (the number of genes is similar to that of yeast), in which two 
thirds cannot be used in meaningful analyses. Sustained effort is therefore required to 
improve functional annotation methods, and contribute to the PlasmoDB gene 
descriptions. Different teams in the world have attempted to address this problem. In 
this paper, we provide an overview of some of the theoretical and practical 
developments that were introduced to improve detection of similarities between 
Plasmodium sequences and distantly related organisms. 
A second difficulty also related to sequence homology detection is the 
reconstruction of molecular phylogenies for malarial genes. Accurate molecular 
phylogenies are particularly important since the Plasmodium cellular organization is 
the result of multiple endosymbioses involving an ancestral alga [3, 35, 36], at the 
origin of a plastid relic, i.e. the apicoplast ([37, 38]; for review: [39-43]). Comparative 
phylogenomics focusing on malarial plant-like genes proved to be a valid strategy to 
detect potential targets for herbicides that act as antiplasmodial [44]. In silico analyses 
combining molecular phylogeny and targeting sequence prediction allowed a first 
rationalized mining of the apicoplast function [45]. The identification of all biological 
processes that have been inherited through lateral gene transfers from the ancestral 
alga (the algal sub-genome) is therefore one of the most important outputs one 
expects from comparative phylogenomics. Although molecular phylogenies of a few 
genes can be achieved with conventional methods, combined with expert visual 
analysis, it is difficult to carry out high-throughput phylogenetic determination at a 
genomic scale. We summarize how the question of automatic assessment of 
orthologies has been addressed, particularly with the OrthoMCL [46] and TULIP [34, 
47] approaches. 
A third difficulty is the representation of knowledge of malaria parasite 
biology. Description of gene function follows the guidelines of the Gene Ontology 
(GO) structured vocabulary [31]. GO is a standard adopted by all the scientific 
community to circumvent problems raised by heterogeneous key word annotations. 
GO also complies with in silico management (and mining) of information. Genes 
coding for enzymes can further be linked to metabolic scheme(s) designed using 
generic methods, i.e. KEGG [48] or MetaCyc [49], or specifically designed for 
Plasmodium, i.e. the Malaria Parasite Metabolic Pathways (MPMP) [50, 51]. 
Pathways based on generic methods do not include representations for cell 
compartmentalization. This information, which has been included in the MPMP, is 
essential to understand the metabolism of water soluble intermediates inside and 
between different cell compartments, and is absolutely critical for pathways involving 
lipophilic compounds localized in disconnected membranes. Eventually, knowledge 
should be represented in a way that is usable for the organization and analysis of 
functional data. We discuss here how each approach complies with these theoretical 
and practical constraints.  
Fourthly, the difficulty of organizing molecular data into knowledge 
representations becomes more pronounced in the analysis of global datasets arising 
from X-omic (transcriptome, proteome, interactome) experiments. We examined the 
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strategies, methods and tools that have been used or designed in order to link malarial 
molecular and functional data in the most versatile way. In particular we describe the 
MADIBA tool developed for local analyses of transcriptomic outputs. 
A fifth difficulty, once a target gene has been identified for possible 
antimalarial intervention, is the process of reaching a decision on the entry into costly 
drug- or vaccine-development programs. Besides experimental validation criteria, in 
silico experiments can be a useful tool to help characterize a possible new target. 
These include determination of protein three-dimensional structure and determination 
of possible binding ligands through in silico protein-ligand docking. To date, the 
structures of less than 70 malaria proteins have been determined and made available 
via the Protein Data Bank [52]. We argue that a repository for all known malaria 
resolved protein structures and structural models should be initiated, curated and 
maintained. No prediction of protein druggability has been investigated. Access to 
such repository might be invaluable for drug discovery projects: virtual screening of 
hundreds of thousands of potential drugs, making use of protein structures of a whole 
family has been achieved using computer grid resources with the WISDOM I project 
[53], and oncoming WISDOM II. 
This review does not pretend to provide any complete panorama on malaria 
molecular, functional and therapeutical genomics or to introduce panaceas. We 
focused on the important difficulties listed here for global analyses and high 
throughput approaches as five major challenges for the future, i.e., 1) comparisons of 
the compositionally atypical malaria gene and protein sequences, 2) high throughput 
molecular phylogeny assessment, 3) usable and interoperable representations of 
metabolic and other biological process, 4) versatile and local integration of molecular 
and functional data obtained from X-omic experiments, and 5) determination and 
prediction of protein structure and subsequent virtual ligand screening on candidate 
therapeutical targets. Linking protein structures with ligand structures is a pivotal step 
for a chemogenomics knowledge base, in which functional and structural knowledge 
deriving from malaria genomics and post-genomics might be connected with the 
space of small molecules containing known and potential drugs. 
Integration of malaria genomic, post-genomic data 
and chemical information: current status and future 
challenges 
Sequence comparisons of compositionally-biased and insert-containing 
malaria genes and proteins.  
The extreme A+T bias in Plasmodium DNA has been a recurrent problem for 
malarial genomics and post-genomics. It was responsible for instability of genomic 
segments in E. coli and difficult assembly during the sequencing process [19]. It 
implied debated modifications and combinations of automatic gene detection methods 
for open reading frame prediction [54, 55]. The nucleotide bias has been demonstrated 
to be responsible for the protein composition bias [56-58]. 
Combined with the frequent insertions seen in malarial proteins, the amino 
acid compositional bias is critical for routine sequence comparison methods, 
particularly because it can compromise the statistical analyses and sorting of BlastP 
alignments [58]. Indeed, an alignment algorithm comes with a statistical model 
implemented in the code, particularly in the Blast package [59], on which users rely to 
assess the significance of the alignment, and to sort them. It is therefore difficult to 
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discuss the current view on sequence comparison methods and statistics 
independently. Two major statistical models are used to test alignment scores. The 
most common test is an estimate of the E-value (short for Expectation value), i.e. the 
number of alignments one expects to find in the database by chance, with equivalent 
or better scores. It can be determined from the complete distribution of scores. The 
BlastP associated statistics defined by Karlin and Altschul [59] are based on the 
probability of an observed local alignment score according to an extreme value 
distribution. The validation of the Karlin-Altschul E-value computation model 
requires two restrictive conditions: first, individual residue distributions for the two 
sequences should not be ‘too dissimilar’ and second, sequence lengths ‘should grow 
at roughly equal rates’ [59]. Validity restrictions listed here are fully acceptable when 
dealing with protein sequences of average lengths and amino acid distribution, and 
BlastP is a good compromise for batch analyses of genomic outputs. However, the 
compositionally biased proteome of Plasmodium falciparum fall outside of the 
validity domain for a BlastP comparison with unbiased sequences [58, 60]. One of the 
reasons explaining that 60 % of the Plasmodium sequences did not have any apparent 
homology with sequences from other genomes may not be that most malarial genes 
are unique in the living world, but that the BlastP semi-automatic annotation 
procedure was technically limited. Some missed sequences could be retrieved by 
adding protein structural information (such as hydrophobic cluster analysis, [61]), but 
these methods require visual expertise and cannot easily be automated. Iterating the 
BlastP procedure has also proven to be helpful in detecting missed homologies [62], 
providing evidence for the initial failure of alignment significance detection. 
An alternative method to assess the relevance of a pairwise alignment was 
introduced by Lipman and Pearson [63]. It uses the Monte Carlo techniques to 
investigate the significance of a given score calculated from the alignment of two real 
sequences. It can be used to sort results obtained by any comparison methods, 
including BlastP, although this has not yet been achieved at a massive scale. It is 
currently used to estimate the probabilities of Smith-Waterman comparisons [64]. The 
asymptotic law of Z-value was shown to be independent of sequence length and 
amino acid distribution [65] and is therefore fully valid for malaria sequence 
comparisons. Bastien et al. [60] demonstrated the TULIP theorem (theorem of the 
upper limit of a score probability) assessing that Z-values can be used as a statistical 
test, a single-linkage clustering criterion and that 1/Z-value2 was an upper limit to the 
probability of an alignment score whatever the actual probability law was. From the 
TULIP theorem and corollaries [47, 60], the comparison of a protein to a given 
reference sequence a, weighed by an alignment score, is characterized by a bounded 
probability that the alignment is obtained by chance. In practice, a Z-value table can 
be analyzed using the TULIP theorem to detect pairs of proteins that are probable 
homologues following a Z-value confidence cutoff. For instance, a Z-value above 10 
allows an estimate that the alignment is significant with a statistical risk of 1/Z-value2, 
i.e. 0.01. A version of the BlastP algorithm, implemented with Z-value statistics, 
which should be helpful to refine malaria sequence comparisons, is currently beta-
tested under the supervision of Olivier Bastien at Grenoble University, and will be 
made available at the Pretoria University ACGT web portal. 
Improvement of automatic annotation procedure are therefore expected, in 
particular by combining sequence comparisons with GO term associations (e.g. 
GOtcha; [33]) a complementary approach to the annotation based on the combination 
of GO terms with functional X-omic response patterns (e.g. Ontology-based pattern 
identification - OPI - following the guilt-by-association principle; [66]) (see below). 
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Genome-scale assessment of malaria molecular phylogenies 
The amino acid compositional bias and high insert content of malaria proteins 
is also a disturbing factor when attempting to reconstruct phylogenies. Conventional 
methods used for phylogeny reconstructions based on multiple alignments can be 
used in conjunction with visual judgment, (e.g. [67]), with qualitative decisions on 
how protein segments "align well". However, such manual pretreatment cannot be 
undertaken for all known genes. Alternatively, high throughput molecular 
phylogenies can be derived from massive all-against-all comparisons, based on 
pairwise alignments [68]. The questions of the statistical accuracy and maintenance of 
high throughput phylogenetic reconstruction are critical when including 
compositionally atypical and high insert containing sequences.  
The output of an all-by-all comparison of n protein sequences is an n x n table. 
According to the output table processing, it can be either totally recomputed at each 
database update, or stored and updated by computing complementary tables. 
Information is extracted from the output table to help reduce complexity and diversity 
at the sequence level. Sets of sequences sharing features are named "clusters" [69].  
A first massive comparison project, OrthoMCL, was designed to cluster 
malaria genes based on their sequence similarity with genes of 55 other genomes (> 
600,000 sequences), using the BlastP algorithm and Karlin-Altschul E-value statistics 
to build the all-against-all comparison table [46, 70]. As mentioned above, and 
discussed recently [68] for massive comparisons based on BlastP/E-values, i.e. COG 
[71], Tribe [72], ProtoMap [73], ProtNet [74],  SIMAP [75] and SYSTERS release 4 
[76], there is no theoretical support to justify that an E-value table can be converted 
into a rigorous and stable metric. The handling of the output n x n table of E-values 
requires pragmatic post-processing normalization, including asymmetric corrections 
of E-values obtained after permutation of the two aligned sequences or consensus E-
value computation after alignment with different algorithms. The E-value table can be 
converted into a Markov matrix (e.g. Tribe, SIMAP, OrthoMCL), or a close graphic 
equivalent, i.e. graphs connecting protein entries with E-values as weights for graph 
edges (e.g. COG, ProtoMap, SYSTERS), a representation that has been exploited in 
the OrthoMCL project. The protein sets are organized either by detecting graphs and 
sub-graphs following pragmatic rules, with granularities depending on E-value 
thresholds, or by distance clustering using E-value as a pseudo-metrics, or by 
Markov-random-field clustering. None of the organization of the protein sequences 
obtained through these methods can be named a spatial projection, and none of the 
obtained clusters can be represented as a phylogenetic reconstruction. Eventually, the 
economy of computing E-values in an all-by-all comparison experiment is lost in the 
updating process that requires a complete re-calculation. In spite of these drawbacks, 
massive comparisons based on BlastP/E-values have been undertaken because they 
were less CPU-demanding than other methods. The OrthoMCL clustering method 
based on BlastP/E-value represents therefore a pragmatic reduction of the protein 
diversity, and phylogeny reconstruction require post treatments within each clusters. 
OrthoMCL flags probable orthologous pairs identified by BlastP as reciprocal best 
hits across genomes. Access to OrthoMCL groups is linked to the PlasmoDB GUS 
underlying database, allowing multiple queries with other PlasmoDB data and 
information, and allowing additional cross-species / cross-phylum profiling of the 
BlastP/E-value-supported orthologues. 
A more CPU-demanding alternative method for massive all-against-all protein 
sequence comparison uses Smith-Waterman/Z-values rather than BlastP/E-values. 
This method has been initiated for the ClusTR protein sequence clustering, underlying 
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the UniProt/Integr8 knowledge base at the European Bioinformatics Institute, EBI 
[77]. Because of the properties of the Z-value statistics detailed above, it is the 
solution of choice when comparing compositionally biased and high-insert containing 
sequences. Additionally, for any set of homologous proteins, it is possible to measure 
a table of pair-wise divergence times and build phylogenetic trees using distance 
methods [47]. These trees are called TULIP trees. TULIP trees were compared to 
phylogenetic trees built using conventional methods, for instance the popular PHYLIP 
[78] or PUZZLE [79] methods based of multiple sequence alignments. TULIP trees 
proved to perform as well in any unbiased sets of proteins. Moreover, some 
phylogenetic inconsistencies in trees built with multiple-alignment based methods, 
particularly including subsets of compositionally biased sequences, or with low 
bootstrapping values, could be spectacularly solved with the TULIP tree [47]. An 
advantage of the phylogenetic inference from the CSHP over that obtained from 
multiple alignments lies precisely in the TULIP tree construction from pair-wise 
alignments. Whereas the addition or removal of a sequence can deeply alter the 
multiple alignment result, and the deduced phylogeny, the Z-value and divergence 
time tables that serve to reconstruct the TULIP trees are the result of a Monte Carlo 
simulation, which is a convergent process at the level of the pair-wise comparison and 
is not altered by database updates. As a result, whereas a phylogenetic database 
computed from multiple alignments would require a complete and increasing 
computation for any update, the TULIP tree calculation simply requires the 
calculation of the {new}-by-{old} and {new}-by-{new} Z-values and divergence 
times. A mapping of each Plasmodium sequence can therefore be obtained and 
updated following all-against-all pairwise comparisons based on Z-value statistics. 
The CPU-cost required by the Smith-Waterman comparison method and by the 
Monte-Carlo simulation used to compute Z-values will be compensated in the future 
by implementing Z-values on the BlastP heuristics. A high-throughput assessment of 
molecular phylogenies of Plasmodium genes based on BlastP/Z-value, including all 
recorded genes in public databases, will therefore be feasible and upgraded at the pace 
of public database updates. 
User access to molecular phylogenies, which has been designed in the 
OrthoMCL project in a very practical and user friendly way, is essential to mine the 
genome for clues to therapeutic opportunities. The most obvious approach is to detect 
protein sequences that are excluded or diverge strongly from the mammalian 
proteome. More subtly, the question of the plant/algal sub-genome of Apicomplexans 
has been demonstrated to be a source of therapeutic targets for herbicidal drugs (e.g. 
apicoplast lipid - fatty acid, isoprenoid -syntheses, plant-like targets localized outside 
plastids - folate metabolism, tubulin -, etc.). Criteria for confirmation of a plant/algal 
sub-genome in P. falciparum include molecular similarities with plant genes, and will 
therefore benefit from future progress in high-throughput molecular phylogenies. 
Information on sequence and sequence similarity are not sufficient to highlight 
functions that are, for instance, unique to plants: they have to be linked to appropriate 
knowledge representation of the biological function of each gene and each process in 
which gene products play their roles. 
Knowledge representations of the biological function 
Having in hand a table of gene entries, with summarized annotations is not 
sufficient to handle genomic information. Data can be organized based on biological 
principles so as to reflect our current knowledge at best, and to be viewed at a glance 
in global X-omic experiments, or for comparative purposes. Biological (and chemical) 
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knowledge is primarily produced in the form of research publications, books, patents 
and other un-structured texts, and since two decades in structured databases 
(biologists are used to fill Genbank forms prior to paper submissions). The general 
principles for the in silico organization of knowledge are therefore based on more or 
less rigorous definitions of semantic networks. Data and information can be organized 
as semantic networks, following combinations of ontologic hierarchies and 
praxeologic schemes [80]. In brief, an ontological hierarchy is designed to organize 
entities (here biological or chemical entities) following inclusion/subsumption 
principles ("A" is part of, is a component of, etc. "B"). Best known examples are the 
taxonomic trees ("species" is part of "genus", etc.) or the Gene Ontology, or GO [31], 
although this later was built from a lose definition of the ontology (see below). A 
praxeologic scheme is designed to organize the activity, the function achieved by an 
entity (for instance the enzymatic activities caused by proteins, or the biologic effect 
caused by drugs) based on the transformation or alteration of an entity into another, 
through time ("C" is converted into "D"). By contrast with ontologies, which should 
be stable and non-conflicting hierarchies, praxeologies can describe cyclic processes 
and can vary over time. Best know examples are metabolic graphs and fluxes, and 
their variations in different physiological conditions. Interestingly, the enzymatic 
activities can be organized following hierarchical principles (e.g. the EC numbers 
proposed by the Enzyme Commission) and a praxeologic scheme such as a metabolic 
pathway is therefore linked to one or more ontologies for the metabolites (hierarchical 
categorization of molecules) and for enzymes (hierarchy following the GO, the EC, 
etc.). In practice, although they are of very distinct nature, ontologic hierarchies and 
praxeologic schemes are handled as semantic networks, called "ontologies" senso 
lato.     
Following recommendations of the Gene Ontology (GO) consortium [31], 
malaria gene function was defined using a semantic network organized in three 
hierarchical axes, i.e. "molecular function", "biological process" and "cellular 
component", according to a controlled hierarchical vocabulary. The GO-based 
annotation circumvents the problems raised by heterogeneous key word annotations, 
allowing subsequently a cross-species comparison with genomes annotated similarly, 
and complies with in silico management requirements. Genes thus annotated can 
further be embraced in higher order representations of biological knowledge. 
Concerning enzymes, entries can be linked to graphical representations of the 
metabolic reactions they catalyze. To that end, in the same way genes were defined 
following the GO procedure, enzyme substrates and products are defined following a 
chemical ontology (CO), and the reaction itself has to be defined following an 
enzymatic reaction ontology. A reaction can be viewed as a small graph in which the 
enzyme is associated with the line that connects the nodes corresponding to the 
substrates and products. Metabolic pathways are connected by shared nodes, and can 
be viewed at different scales. Current representations of malaria metabolism have 
been made available using generic methods, i.e. KEGG [48, 81] or MetaCyc [49, 82, 
83], or specifically designed for Plasmodium, i.e. the Malaria Parasite Metabolic 
Pathways (MPMP) coordinated by Hagai Ginsburg at the Hebrew University of 
Jerusalem [50, 51].  
The Kyoto Encyclopedia of Genes and Genomes (KEGG) resource provides a 
set reference of metabolic schemes, manually designed so as to represent all possible 
primary metabolic reactions, and formatted with the KEGG Markup Language 
(KGML) [48]. These reference schemes can be explored on the KEGG web portal, 
with a very clear view of the global metabolic map, connecting all pathways. 
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Organism-specific schemes are generated, based on sequence similarities (using the 
KEGG Orthology, or KO orthologue identifier) with references to the KEGG Gene 
catalogs. Thus 79 metabolic schemes have been generated for P. falciparum. Each 
scheme provides links to metabolite (substrates, products, co-substrates) information, 
and enzyme descriptions following the Enzyme Commission (EC) classification. EC 
numbers give access to multiple sequence alignments, protein motifs, genomic 
mapping, links to Genbank, UniProt, PDB, etc. Tilling KEGG schemes from different 
organisms highlights metabolic similarities and differences, and could be of help for 
anti-malarial purposes, highlighting for instance metabolic reactions occurring in 
Plasmodium and not in humans. However, the maps are designed based on the 
enzymatic reactions and, for instance, the fatty acid synthesis due to the type 1 fatty 
acid synthase (FASI, a multiprotein complex) from the human cell cytosol, strictly 
overlaps with the type 2 fatty acid synthase (FASII dissociated enzymes) from the 
Plasmodium apicoplast. Information on the protein structure and cell 
compartmentalization of the enzymes would have been sufficient to distinguish 
between FASI and FASII. Furthermore, metabolites that are generated in one 
compartment (i.e. diacylglycerol generated in one of the numerous cell membranes) 
may not be available for an apparent downstream reaction occurring in another 
compartment. Thus, used without caution, the KEGG schemes may seem to be fully 
valid for the entire living world, with a misleadingly clear and fully cross-connected 
global overview of metabolism, and can lead to unrealistic representations. The 
missing enzymes, which have been experimentally assayed, are not shown, and it is 
unclear whether gaps within pathways are due to absent enzymes or to incomplete 
data. Additionally, the KEGG representation is not intended for the design of schemes 
other than those pre-defined. KEGG outputs need therefore to be reexamined for 
accuracy of interpretation (see below). 
As an alternative, the design of MetaCyc schemes for Plasmodium, called 
PlasmoCyc, has been initiated [49, 82]. As for KEGG, a reference of the complete 
metabolic pathways has been designed manually and loaded in a MetaCyc database. 
In contrast with the fully connected overview of the KEGG metabolic map that can 
make the user overconfident, the MetaCyc global view of metabolism is fragmented, 
reflecting knowledge gaps, incomplete design of some pathways (such as the tricky 
pathways for lipid syntheses), and the versatility of the MetaCyc tool for 
implementation of new schemes. Using P. falciparum gene annotation and 
information of the MetaCyc reference database, the PathoLogic module of the 
Pathway Tool Software [84] allows the generation of a Pathway/Genome Database 
(PGDB). A total of 113 metabolic pathways (complete or fragmented) have been 
generated for P. falciparum. As in KEGG, each graph gives access to metabolite, 
reaction and enzyme information. The Gene-Reaction Schematic (GRS) 
representation allows a visualization of the relation between the genes, the enzymes, 
the catalyzed reactions, even in the case of complex or multienzymatic proteins. This 
model is therefore useful to distinguish for instance FASI and FASII proteins. It is 
further useful for Plasmodium proteins that are often multienzymatic. For each 
reference pathway, the occurrence or absence of enzyme homologues in the 
Plasmodium genome is documented. As in the case of KEGG, compartmentalization 
information is missing from the pathway model, in spite of some effort to highlight 
some specific pathways (for instance the apicoplast fatty acid synthesis). 
A synthetic representation of Plasmodium biological processes can further be 
viewed at the Malaria Parasite Metabolic Pathways web portal [50]. Among 120 
schemes representing numerous cellular processes, half represent metabolic pathways 
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and were fully designed for malaria researchers. All schemes were built using KEGG 
pathways, cleaned of irrelevant information and curated by international experts. The 
quality of each representation is therefore very high and specialized, and benefits 
from a sustained effort in biological and molecular investigation and validation. 
Missing data are concisely documented. Most importantly, enzyme subcellular 
localization is shown. Graphs are not automatically generated, but drawn by experts. 
While MetaCyc graphs are self generated taking into account all information of the 
underlying database, the MPMP scheme are not self generated: in particular, the 
subcellular localization representation is not generated automatically from a 
subcellular attribute filled in the underlying database. Thus, although the MPMP 
representations are of higher quality, their update is not dynamic and cannot be used 
for in silico graph-based treatments. 
From this short overview, it is clear that metabolic representations should be 
carefully used. On one hand, generic approaches (KEGG, MetaCyc) do not include 
cell compartmentalization data and the chemical ontology for lipids is not finished. 
On the other hand, the curated MPMP representations are based on high-quality data 
but they are static, with no graph management tools, giving click-access to remote 
information. Future challenge will be to design underlying models for building graphs 
from genomic data (following the GO), metabolite data (following a stable Chemical 
Ontology), reaction connections and compartmentalization information for both gene 
products and metabolites. Construction of PlasmoCyc benefited from information of 
the MPMP [50, 82], and MPMP was designed after cleaning KEGG schemes. Models 
for other knowledge bases and graphs should benefit from the important effort of the 
MPMP in defining metabolic and other biological processes. 
Connecting functional schemes and ontologies with post-genomic global 
functional analyses 
The application of functional genomics strategies to assign functionality to 
each gene product of an organism has recently attained increased attention in the field 
of post-genomics research of Plasmodia, particularly oriented towards the discovery 
of new drug leads (therapeutics) and novel drug targets. This includes the 
understanding of the transcriptome, proteome and interactome of the parasite to 
elucidate mode-of-action of inhibitory compounds, allow optimization of such 
inhibitor activities, explain resistance mechanisms to known drugs, chemically 
validate potential drug targets and ultimately identify and/or functionally describe 
new drug targets (Figure 1).  
The P. falciparum transcriptome has been extensively investigated resulting in 
comprehensive profiles of transcript expression throughout the complete life cycle of 
the parasite [85, 86]. The overall conclusions demonstrated that the majority (~87%) 
of the predicted genes are actively transcribed during the lifecycle but that 20% are 
specific of the intraerythrocytic developmental cycle and are produced in a periodic 
nature in a ‘just-in-time’ fashion. These early reports have been followed by 
investigations designed to answer numerous biological questions, including 
transcription and post-transcription specific aspects of the regulation of protein 
expression, transcriptional machinery and inheritance, interstrain conservancy, 
gametocytogenesis and antigenic variation control mechanisms [87-91]. A high 
degree of correlation exists between the in vitro and in vivo transcriptomes of P. 
falciparum with an overexpression seen for genes encoding a sexual stage antigen as 
well as gene families that encode surface proteins, providing interesting new vaccine 
candidates [92, 93].  
 - 11 - 
Although transcriptomics remains the most comprehensive, highest-
throughput methodology to provide vast amounts of data on a global level, it does not 
specify the dynamic, functional units of a cell. Proteomics studies are essential to 
conclusively prove mechanistic changes and explain global protein expression 
profiles, differential protein expression, posttranscriptional control, posttranslational 
regulation and modifications, alternative splicing and processing, subcellular 
localization and host-pathogen interactions (Figure 1). Reassuringly, there is a good 
correlation between the abundance of transcripts and the proteins encoded by these 
during the P. falciparum lifecycle [87, 88] with a majority of discrepancies attributed 
to a delay between transcript production and protein accumulation. Analysis of the P. 
falciparum proteome [94] and a comprehensive and integrated analyses of the 
genome, transcriptome and proteome of P. berghei and P. chabaudi chabaudi, which 
represents the state-of-the-art of functional genomics applied to the lifecycles of 
Plasmodia [95, 96], indicated that over half of the proteins in these parasites were 
detected solely in one stage of the lifecycle. This implies a considerable degree of 
specialization at the molecular level to support the demanding developmental program 
and suggested a highly coordinated expression of Plasmodium genes involved in 
common biological processes.  
No single protein has physiological meaning alone and part of its mechanistic 
importance depends on its interactions with other proteins and cellular components. 
In-depth understanding of the protein-protein interaction network (defined as 
interactome) can provide insights into the function of proteins, regulatory mechanisms 
and functional relationships of these (Figure 1). An extensive protein-interaction 
study of P. falciparum (nearing global-type analysis) combining interaction 
information with co-expression data and GO annotations indicated unique 
interactions, identified groups of interacting proteins implicated in various biological 
processes, and predicted novel functions to previously uncharacterized proteins [97]. 
Interestingly, comparison of the Plasmodium interactome with that from other 
organisms indicated a marked divergence with very little conservation with other 
protein complexes [98].  
The abovementioned X-ome datasets are therefore now available for in silico 
data mining approaches. As such, data mining of the transcriptome using an extensive 
sequence similarity search identified 92 putative proteases in the P. falciparum 
genome, 88 of which are actively transcribed [99]. This strategy has also been applied 
to the kinase family [100]. The transcriptome datasets are nowadays extensively 
utilized in PlasmoDB, MPMP and other specialized sites [101]. PlasmoDB 
additionally has links to proteome data and also allows access to the interactome data. 
Proteome experiments based on 2D-gel electrophoresis can furthermore be aided by 
Plasmo2D software to allow the identification of proteins in such platforms [102].  
 
<Figure 1> 
 
An important question in mining different global X-omic datasets is how they 
can be compared. Draghici et al. [103] made clear that the inconsistencies between the 
various microarray platforms (in situ synthesized short oligos, longer oligos, spotted 
oligos or cDNAs) are so high that it is almost impossible for the moment to compare 
results from different platforms. How can a transcriptomic profile be compared to a 
proteomic profile, given the errors, the linearity of signals and the magnitude of 
variations of each method, and the biological stability and turnover of RNA 
transcripts and of proteins? Is the enzyme profile correlated with the metabolite 
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profile [104]? A pragmatic solution is to avoid the multiplicity of methods and by 
agreeing on some standards [103, 105-107]. Although "global" invariant references 
might not exist, it is nevertheless worth trying to find in large gene expression 
matrices the most invariant (or less variant) genes [106]. This quest is of general 
concern and is currently one of the challenges proposed by the European Conferences 
on Machine Learning and the European Conferences on Principles and Practice of 
Knowledge Discovery in Databases [106, 109]. In the absence of absolute references 
and standards, outputs from malaria X-omic experiments should be analyzed and 
compared with caution, particularly when obtained with platforms that are distinct 
from those used to feed the public data repositories. Consequently, in addition to 
referential public repositories for functional genomics, versatile software for local 
analyzes are strongly needed. 
Various tools aim to provide biological interpretation of gene clusters but 
these mostly specialize in only one or two types of analyses. FatiGO [110], GeneLynx 
[111] and Gostat [112] are powerful tools for Gene Ontology mining; GoMiner [113], 
MAPPFinder [114] and DAVID [115] use GO and metabolic pathway interpretation 
whereas GeneXPress [116] and MiCoViTo [117] use metabolic pathways and 
incorporate transcription regulation visualization. Improvements on these include a 
web interface called MADIBA (MicroArray Data Interface for Biological Annotation, 
[118]) that has been initially designed for malaria transcriptomics (Dr. C. Claudel-
Renard, personal communication). This interface links a relational database of various 
data sets to a series of analysis tools designed to facilitate investigations of possible 
reasons for co-expression of clusters of genes (e.g. from gene expression data) and to 
deduce possible underlying biological mechanisms. Clusters of co-expressed genes 
are automatically subjected to five different analytical modules including 1) search for 
over-represented GO terms in clusters, 2) visualization of related metabolic graphs 
with KEGG representations, 3) chromosomal localization, 4) search for motifs in the 
upstream sequences of the genes and finally 5) Plasmodium-specific genes without 
human homologues. MADIBA analysis of the transcriptome dataset from Le Roch et 
al. [85] resulted in an improved annotation of the Plasmodium genes (41% vs. 37%) 
and characterization of 6 additional clusters with GO annotations, of which one 
exclusively contained glycolysis in its entirety (except for fructose-bisphosphate 
aldolase) and another identifying gene as potential as drug targets due to their 
Plasmodium-specific characteristics. Therefore, MADIBA allows versatile analyses 
of a vast variety of transcriptomic profiles. These analyses can highlight potential 
drug targets by providing functionality to co-clustered expressed genes in a guilt-by-
association manner, including those of un-annotated proteins, by predicting co-
regulated expression via chromosomal localization as well as the identification of 
motifs for cis-regulatory elements and lastly by identifying unique Plasmodium-
specific genes involved in specific biological mechanisms. 
With the advent of integrative investigations of datasets from the 
transcriptome, proteome, interactome etc. new analysis tools are being developed 
including a Partial Least Squares (Projection to Latent Structures–PLS) method which 
has been used to integrate yeast transcriptome and metabolome data [119]. Linear 
modeling was used to investigate the changes in the transcriptome due to 
environmental perturbations and, assuming that the metabolome is a function of the 
transcriptome, the metabolic variables were modeled with PLS. A genome-wide 
investigation of protein function was recently performed by computationally 
modeling the P. falciparum interactome [120] to elucidate local and global functional 
relationships between gene products. This novel approach entailed an integration of in 
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silico and experimental functional genomics data within a Bayesian framework to 
create the network of pairwise functional linkages. This resulted in predicting 
functionality based on associations between characterized and uncharacterized 
proteins for 95% of the currently annotated hypothetical proteins in the P. falciparum 
proteome. Only 107 hypothetical proteins show interaction with other hypothetical 
proteins potentially representing new pathways or previously uncharacterized 
components of known pathways. 
Less than 500 of the known pharmaceutical drug targets act in the mechanism 
of currently known drugs. This brief overview shows that the integration and mining 
of global functional genomic experiments are in the frontline in drug discovery 
processes [121, 122]. Malaria X-omics data provide comprehensive information to, 
amongst others, understand the mode-of-action (MOA) of inhibitory compounds, 
allow optimization of drug action, validate drug targets (chemical validation 
strategies), identify families of genes/gene products that are more amenable as drug 
targets (‘druggable genes’), annotate the function of hypothetical proteins by 'guilt-
by-association' and point out specialized gene expression regulation systems (See 
Figure 1) [123].  
In the case of drug treatments, the sought effects on the metabolism of targeted 
tissues or organisms include up- or downregulation of the protein target(s), the 
upregulation of detoxification pathways (cytotoxic responses) and the upregulation of 
alternative or compensatory pathways of the affected organism that can be reflected in 
changes in the transcriptome/proteome of the organism. The characterization of the 
transcriptional response induced by drug challenge has been applied with success in 
the antibacterial field, creating reference compendia of expression profiles after drug 
challenge that provide insight into a drugs’ MOA [123-125]. Transcriptional profiling 
of drug challenged malaria parasites has been limited to only a few studies to date 
including Serial analysis of gene expression (SAGE) of chloroquine treated parasites 
[126], a high-density short-oligonucleotide array study on parasites treated with 
phosphatidylcholine biosynthesis inhibitors [88] and custom arrays originating from 
suppression, subtractive hybridisation (SSH) libraries on parasites treated with 
polyamine biosynthesis inhibitors [127]. Drug-specific transcriptional responses were 
seen in the chloroquine and polyamine inhibition studies indicating the presence of a 
feedback signaling mechanism. Le Roch et al. [88] compared transcriptional 
responses with proteome analyses and showed that more pronounced changes were 
induced at the protein level after drug challenge. This is also true for antifolate 
inhibited parasites where a marked increase were seen in folate biosynthesis protein 
levels upon treatment with inhibitors against DHRF-TS [128]. Global-level proteome 
response analysis of the combination of artemether and lumefantrine also revealed 
drug-specific changes in the proteome [129]. Subproteomic investigations have 
additionally become particularly important to determine the molecular binding 
partner/target protein of an inhibitory compound and/or to describe the mode-of-
action of such compounds. This has been applied to ferriprotoporphyrin IX were 
identified [130], kinase inhibitors [131] and the quinoline family of compounds [132].  
Any of the abovementioned strategies are potential starting points to the 
discovery of unsuspected drug targets in P. falciparum, whether it is a new/additional 
functionality that is ascribed to a known protein or the characterization of novel 
function of a previously ‘unknown’ protein. As the hypothetical proteins represent 
more than half (~60%) of the malarial proteome (see above), these are some of the 
most attractive areas to the drug target discovery effort. The basic rationale behind 
using expression profiles to assign functionality to genes is based on the principle of 
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guilt-by-association [133, 134] in which genes coding for proteins with similar 
functionality often exhibit the same expression profiles and protein-interacting 
partners. Coincidentally, the expression profiles of genes specific to a given organelle 
also display similar expression patterns. This principle has been applied with 
unsupervised robust k-means clustering [85]. Improvements on this clustering 
approach were proposed using a semi-supervised clustering method called ontology-
based pattern identification (OPI) [135]. OPI uses previous gene annotation data to 
generate clusters with greater specificity and confidence whose members then 
additionally share the same expression profiles. However, Llinás and del Portillo 
[136] warns against using only classical guilt-by-association methods, showing that 
many genes that are functionally unrelated show similar expression profiles during the 
asexual development of P. falciparum.  
Malaria protein structures and virtual ligand screening on candidate targets 
Vital malaria proteins may have no counterpart in humans or sequence 
dissimilarity with their human homologues that may be sufficient to become a 
therapeutical target without disturbing essential function in the human host. The 
literature on potential protein targets for anti-malaria treatments is already crowded, 
and will hopefully be enriched and better documented in the future. Once a target has 
been identified, an important decision is whether or not to enter into costly drug- or 
vaccine-development programs. Determination or prediction of the target three-
dimensional structure and in silico experiments can be achieved to connect these 
biological targets with the pharmacological space of small compounds [137], and 
assist this decision and provide initial clues on possible therapeutical strategies.  
 
Malaria protein structures.  
 
The rationalized identification of new inhibitors depends on possession of 
structural information. As for any other organism, the primary problem is obtaining 
high and pure protein yields for crystallization trials. Recombinant expression of 
malarial proteins in E. coli is notoriously difficult, however. A number of problems 
are typically encountered. The A+T richness results in substantially different codon 
usage compared to E. coli. Plasmodium genes are also typically much longer than 
their homologues in other organisms, as are the resulting proteins. Increased protein 
size is due mostly to long protein inserts with generally little homology to cognate 
enzymes. These inserts tend to be disordered and of low complexity, resulting in 
proteins that are not amenable to expression and crystallization. Further problems 
include sporadic mutations of low complexity sequences introduced by E. coli, and 
cryptic prokaryotic translation start sites within malarial genes. Some level of protein 
expression may be obtained by fine control of expression conditions, often a change 
of strain or of complete expression system, addition of rare codon tRNAs, and more 
and more often by production of synthetic genes coding for identical protein 
sequences but with a codon usage optimized for bacteria [138-142]. Mehlin et al. 
[143] recently attempted a wholesale expression of 1000 malarial genes and obtained 
soluble expression for only 63 genes. High predicted disorder, molecular weight, pI 
and lack of homology to E. coli proteins were all negatively correlated with soluble 
expression. 
The difficulty of expressing malarial proteins is reflected by the paucity of 
structures in the Protein Data Bank [144]. At the time of writing there are only 64 
non-redundant Plasmodium protein structures in the PDB (Table 2). In contrast, 
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querying the PDB for human entries (excluding > 90% sequence identity) reveals 
more than 1700 structures. The advent of structural genomics programs (the Structural 
Genomics Consortium, [145]; the Structural Genomics of Pathogenic Protozoa, [146]) 
has increased the throughput of new malarial structures. Since 2003, 56 depositions of 
Plasmodium structures have been made. Whether this trend will continue beyond the 
"low hanging fruit" remains to be seen. 
 
<Table 2> 
 
In lieu of crystal structures for malarial proteins many groups have resorted to 
homology modeling. This approach depends critically on the alignment with template 
structures. Unfortunately the biased nucleotide and amino acid composition (see 
above and [58]) and Plasmodium-specific inserts make it difficult to correctly identify 
core-conserved regions. The presence of inserts often confuses multiple and 
structural-alignment programs. A number of techniques have been used to circumvent 
this problem (see Figure 2). From a first pass alignment, approximate insert positions 
can be determined. Sequences can then be split according to long inserts and re-
aligned. Inserts can vary considerably across different Plasmodium species ([147] and 
C. Claudel-Renard, personnal communication). Therefore, while adjusting an 
alignment for modeling, it is useful to refer to phylogenetically diverse multiple 
alignments including as many Plasmodium sequences as possible (see above, [148]). 
As an adjunct to alignment, independent motif identification (e.g. the MEME system; 
[149, 150]) can be used to fix mistakes that alignment programs frequently make 
when aligning long Plasmodium proteins with homologues [148, 151]. Further 
improvements can be made by using hydrophobic cluster analysis [61] and secondary 
structure predictions to align homologous regions within inserts. Once an alignment 
has been decided on, based on visual assessment, a series of models can be built. 
Because of the high degree of uncertainty that often accompanies alignments used for 
modeling malarial proteins, it is usually not feasible to rectify all structural anomalies. 
But by performing standard quality checks on a large sample of models and 
summarizing the results, it is possible to identify parts of the alignment causing most 
problems. Refined alignments might benefit from species-specific matrices that take 
into account the differences of amino acid distribution between the aligned proteins 
[60, 152].  
 
<Figure 2> 
 
Despite the difficulties with homology modeling of malarial proteins there 
have been some notable successes. Malarial DHFR forms part of a bifunctional 
protein that also carries thymidylate synthase. A number of existing drugs such as 
cycloguanil and pyrimethamine target the DHFR domain, and have been used 
effectively in the past. However drug resistance has evolved that reduces the 
usefulness of this important class of drugs. Hence malarial DHFR has been a popular 
target for homology modeling efforts [153-158]. Toyoda et al. [153] were able to 
identify new inhibitors in the micromolar range. McKie et al. [154] and Lemcke et al. 
[155] could rationalise the pyrimethamine resistance caused by the S108N mutation. 
One of these models was further used to identify new inhibitors acting in the nano- 
and micromolar ranges [154]. Delfino et al. [158] in turn used their model to 
investigate a large number of antifolate resistant mutants. Rastelli et al. [156] further 
explained the cycloguanil resistance/pyrimethamine sensitivity conferred by 
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A16V+S108T, as well as the ability for WR99210 to inhibit both pyrimethamine and 
cycloguanil resistant mutants. A number of new inhibitors were also successfully 
designed. The high accuracy of the alignment used for modelling meant that predicted 
dockings were subsequently confirmed with the crystal structure of the complete 
bifunctional enzyme [159]. Considerable work has also gone into modeling malarial 
proteases essential to the parasite's intra-erythrocytic life stage. A number of these 
models have been used to identify new inhibitors [160-163], although the increasing 
number of crystal structures for these proteases is likely to gradually replace the need 
for homology models (Table 2). 
Apart from the PDB, there is currently no resource that includes all 
Plasmodium protein structures. Both publicly available versions of PlasmoDB (4.4 
and 5) are still incomplete in this regard. PlasmoDB 4.4 only lists P. falciparum 
structures, and there is incomplete overlap between versions 4.4 and 5. PlasmoDB 4.4 
includes a section for >440 modeled structures based on a wholesale modeling 
attempt of >5000 open reading frames documented at [164]. However, at the time of 
writing the actual structures were not available. Furthermore, PlasmoDB 5 also lists 
non-Plasmodium structures, and therefore requires some curating. We argue that a 
dedicated resource for deposition of structures from the Plasmodium structural 
community would be useful. The resource should also include model structures 
subjected to the same rigor as experimental structures in the PDB, including quality 
criteria and scoring. Thus "experimental" details for modeling (alignments, software 
methods etc) should be included. This resource should also allow easy comparison 
with corresponding solved structures enabling evaluation of the communities' ability 
to model this difficult organism.  
Protein structures provide invaluable information for drug or vaccine 
discovery. First, compliance of the structure with known properties of recorded 
pharmaceutical targets (termed "druggable" genes) [165-167] or prediction of the 
occurrence of immunogenic epitopes (termed "immunizable" genes) [168-169], can 
be investigated. Second, having a protein structure in hand is a very early, but 
necessary step, for the in silico prediction of the families of ligands that can interfere 
with protein function.   
 
Virtual ligand screening. 
 
Advances in combinatorial chemistry have broken limits in organic synthetic 
chemistry and accelerated the production throughput. Thus, millions of chemical 
compounds are currently available in private and academic laboratories and recorded 
in 2D or 3D electronic databases. It is often technically impossible and very expensive 
to screen such a high number of compounds using wet high throughput screening 
techniques. An alternative is high throughput virtual screening by molecular docking, 
a technique which can screen millions of compounds rapidly and cost effectively. 
Molecular docking is computer based method which predicts the ligand 
conformations inside the active site of the target as well as an estimate of the binding 
affinity between protein and ligand. It also gives insight about the interactions 
between protein and ligand and allows to generate mode-of-action hypotheses. 
Screening each compound, depending on its structural complexity, requires from a 
few seconds to hours of computation time on a standard PC workstation depending on 
the chosen docking algorithm. Consequently, screening all compounds in a single 
database would require years. However, the problem is embarrassingly parallel and 
the computation time can be reduced very significantly by distributing data to process 
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over a grid gathering thousands of computers [170, 171]. 
Recently, virtual screening projects on grids have emerged with the purpose of 
reducing cost and time. They focused on the development of an in silico docking 
pipeline on grids of clusters [172] but also on the optimization of molecular modelling 
[173]. Pharmaceutical laboratories have also become interested by the grid concept; 
Novartis deployed the first automated modelling and docking pipeline on an internal 
grid [174]. Other projects focused on virtual screening deployment on a pervasive 
grid, or desktop grid, to analyse specific targets [175].  
In mid-2005, the WISDOM (World-wide In Silico Docking On Malaria) 
initiative successfully deployed large scale in silico docking on the European public 
EGEE grid infrastructure [176]. The biological targets were plasmepsins, aspartic 
proteases of Plasmodium responsible for the initial cleavage of human haemoglobin 
[177]. There are ten different plasmepsins coded by ten different genes in P. 
falciparum (Plm I, II, IV, V, VI, VII, VIII, IX, X and HAP) [178]. High levels of 
sequence homology are observed between different plasmepsins (65-70%). 
Simultaneously they share only 35% sequence homology with their nearest human 
aspartic protease, Cathepsin D4 [179]. This and the presence of accurate X 
crystallographic data made plasmepsin an ideal target for rational drug design against 
malaria. 
The main goal of the WISDOM project has been to make use of the EGEE 
grid infrastructure to set up an in silico experimentation environment. Having the 
necessary computing power at hands, scientists from a virtual organization can design 
new large scale test systems for generating new hypotheses. The benefit is that a large 
number of targets can be combined with a very large number of potential hit 
molecules, using different docking algorithms and allowing to chose different 
parameter settings. As discussed above for the X-omic experiments in post-genomic 
platforms, in silico methods pose the same important question in order to mine the 
data, i.e. how they can be compared. The careful input data preparation is a crucial 
step in the process, which has to be performed by experts and be made available for 
the whole scientific community. By sharing the results of virtual screenings in a 
common knowledge space, different experts coming from different fields can jointly 
derive a rational for selecting appropriate combinations of targets, ligands and virtual 
screening methods. 
The WISDOM large scale in silico docking deployment saw over 46 million 
docked ligand-protein solutions, resulting from 2 docking tools, 5 targets, 1 million 
compounds and 4 parameter settings, the equivalent of 80 years on a single PC in 
about 6 weeks. Up to 1700 computers were simultaneously used in 15 countries 
around the world. Post-processing of the huge amount of data generated was a very 
demanding task as millions of docking scores had to be compared. At the end of the 
large scale docking deployment, the best compounds were selected based on the 
docking score, the binding mode of the compound inside the binding pocket and the 
interactions of the compounds to key residues of the protein.  
Several promising scaffolds have been identified among the 100 compounds 
selected for post processing. Among the most significant ones are urea-, thiourea-, 
and guanidino analogues, as these scaffolds are most repeatedly identified in the top 
1000 compounds (see Figure 3). Validating this approach, some of the compounds 
identified were similar to already known plasmepsin inhibitors, like urea analogues 
from the Walter Reed chemical database, which were previously established as micro 
molar inhibitors for plasmepsins [180]. This indicates that the overall approach is 
sensible and large scale docking on computational grids has real potential to identify 
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new inhibitors. In addition, guanidino analogues appeared very promising and most 
likely to become a novel class of plasmepsin inhibitors.  
 
<Figure 3> 
 
The developed and established protocols can be used for coming scenarios. 
Several teams have expressed interest to propose targets for a second computing 
challenge called WISDOM II that should be carried out in late 2006. While docking 
methods have been significantly improved in the last years, docking results need to be 
post-processed with more accurate modeling tools before biological tests are 
undertaken. The major challenges for docking methods still are pose prediction and 
scoring. Molecular dynamics (MD) has great potential at this stage: firstly, it enables 
a flexible treatment of the ligand/target complexes at room temperature for a given 
simulation time, and therefore is able to refine ligand orientations by finding more 
stable complexes; secondly, it partially solves conformation and orientation search 
deficiencies which might arise from docking; thirdly, it allows the re-ranking of 
molecules based on more accurate scoring functions. Efforts are now devoted to 
deploy on the grid both docking and Molecular Dynamics calculations to further 
accelerate in silico virtual screening before in vitro testing.  
Conclusions: toward a chemogenomic knowledge 
space  
In this paper, we examined five aspects of the in silico storage, organization 
and mining of data from malaria genomics and post-genomics, in the context of the 
prediction and characterization of targets and drugs: 1) the comparison of protein 
sequences including compositionally atypical malaria sequences, 2) the high 
throughput reconstruction of molecular phylogeny, 3) the representation of biological 
processes particularly metabolic pathways, 4) the versatile methods to integrate 
genomic data, biological representations and functional profiling obtained from X-
omic experiments after drug treatments, 5) the determination and prediction of protein 
structures and their virtual docking with drug candidate structures. We focused our 
attention on the data management that should be at the genomic scale, including 
multiple species, and should therefore be as reliable as possible. We were concerned 
that a "biological space" should be formatted so as to represent our knowledge and to 
connect genomic data and post-genomic functional profiles in the most versatile way, 
allowing the mining of information with diverse methods (Figure 4a-e). This 
"biological space" should be linked to a "chemical space" that contains all small 
molecules stored in chemolibraries (millions of compounds) including known drugs 
(Figure 4f-h). Thus, we argue that progresses toward a chemogenomic knowledge 
space can benefit on the referential public repositories and particularly UniProt and 
PlasmoDB, on recent theoretical advances in genomics and post-genomics data 
management and mining and on the power of computer grids (Figure 4). 
 
<Figure 4> 
 
Genomic data (Figure 4a), i.e. protein sequences, can be organized based on 
sequence similarity (Figure 4b). This projection of protein sequences should allow the 
high throughput reconstruction of molecular phylogenies both at the intraspecific 
(connecting paralogs and alleles) and interspecific (connecting homologues among 
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which orthologs) levels, following statistically accurate methods (Figure 4b). This 
task is difficult because of the compositional bias and high insert content of malaria 
sequences. Statistically valid protein sequence comparisons are now available to 
allow genome scale alignment and high throughput phylogeny reconstruction (named 
TULIP), including malaria atypical sequences, and providing quality scores on which 
one can rely after automatic genome scale treatments. Benefits from the TULIP 
method include an easy upgrade and update of the obtained protein spatial projection. 
Another substantial side of a biological space contains representations of our 
knowledge of biological processes, using stable ontologies, and dynamic graph 
representation (Figure 4c). Here, efforts are still needed to improve existing 
representations of the metabolism and numerous projects are under progress, most 
importantly PlasmoCyc and PMPM. The PlasmoCyc existing metabolic graphs have 
the advantage of being more easily updated and usable for in silico mining methods, 
as long as the output is examined by biological experts. In a brief overview of malaria 
X-omic profiling, we introduced some tools allowing a linkage between genomic 
data, biological process representations and global functional profiles (Figure 4d). 
There is still a large diversity of data treatment and mining strategies, reflecting the 
diversity of technologies and mining methods. This step is one of the doors to connect 
the biological space with the chemical space, following the "reverse chemical genetic" 
way, i.e. "from known drugs to biological response" (toxicity, mode of action). Basic 
analytical tools like MADIBA and sophisticated mining approaches will be needed to 
understand and compare the biological responses to anti-malarial drugs. The other 
door to connect the biological space and the chemical space follows the "direct 
chemical genetic" way, i.e. "from known biological target to drug candidate". We 
argue that in addition to crystal structures of malaria proteins, the automated structural 
annotation of the malaria proteome should be initiated (Figure 4e). Based on protein 
structure information, virtual docking campaigns such as the WISDOM challenges 
can be achieved using the power of computer grids. 
This paper did not review the "chemical" side for chemogenomics space. By 
numerous aspects the in silico organization of the small molecules stored in 
chemolibraries (Figure 4f) was not achieved the way biological information was. 
Clustering of small molecular structures based on properties is highly debated (Figure 
4h). Collections of small molecules are generally designed to obey the pragmatic 
Lipinski's "rule of five" [181] making them likely candidates for drug discovery. 
Numerous studies are under progress in order to identify which small molecule 
descriptors can comply with chemogenomic approaches (e.g. the Accamba project for 
the analysis of chemolibraries and the building of bioactivity models; [182]). A 
chemical ontology (CO) has been recently introduced [183], but it has not yet been 
used and validated by the scientific community the way the GO was. A database for 
Chemical Entities of Biological Interest (ChEBI) has also been launched [184]. The 
modeling of the three-dimensional structures of small molecules (Figure 4g) can be 
predicted by numerous public or commercial methods which should be examined with 
attention (see the WISDOM challenges). PubChem, a repository for molecules acting 
on biological targets was recently launched [183, 185] and the UniProt protein 
knowledge base was recently upgraded to report toxic doses of small molecules on 
proteins [186, 187], however these initiatives are just starting points. Access to an 
ocean of small molecular structures and to a deluge of biological sequences raises an 
enthusiastic challenge: “The goal for the coming decades will be to explore the 
overlap between chemistry space and protein space” [188]. Is this prediction 
exuberant? From the methodological survey summarized in this paper, we believe that 
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this next milestone for malaria research is not out of reach. 
Beyond virtual screening, the grid technology provides the collaborative IT 
environment to enable the coupling between molecular biology research and goal-
oriented field work [189]. It proposes a new paradigm for the collection and analysis 
of distributed information where data are no more to be centralized in one single 
repository. On a grid, data can be stored anywhere and still be transparently accessed 
by any authorized user. The computing resources of a grid are also shared and can be 
mobilized on demand so as to enable very large scale genomics comparative analysis 
and virtual screening. A longer term perspective is therefore to enhance the ability to 
share diverse, complex and distributed information on a given disease for 
collaborative exploration and mutual benefit. The concept of a knowledge space is to 
organize the information so that it can be reached in a few clicks. This concept is 
already successfully used internally by pharmaceutical laboratories to store 
knowledge [175]. The grid permits the building of a distributed knowledge space so 
that each participant is able to keep the information he owns on his/her local 
computer. A set of grid services would particularly take advantage of the 
developments in the area of semantic text analysis for extraction of information in 
biology and genome research. (Figure 4, lower part). The literature on malaria 
biology, physiopathology and medicinal chemistry is, at least in significant parts, 
stored as unstructured texts that make an invaluable source of knowledge which 
access depends on advances in terminology analysis and term extraction methods. A 
first attempt at using terminology analysis for the “harvesting” of relevant concepts in 
a defined disease area has been undertaken in another biomedical grid project, the 
recently started EU Integrated Project @neuRIST [190]. In this project, terminology 
analysis lead to the refinement of a disease-specific text corpus and provided a 
shortlist of relevant terms. Moreover, not only the genes associated with the defined 
disease area could be identified by automated methods, but also single nulceotide 
polymorphisms (SNPs) published for these disease-associated genes, could be 
automatically identified (Dr. Laura Furlong, IMIM, Barcelona, personal 
communication). An important focus of future activities in this project is the 
construction and validation of fine-granular disease-specific ontologies.  This concept 
can easily be adopted for a knowledge base on any disease, including malaria. 
Existing databases can be complemented by this automatically generated semantic 
layer, which subsequently would also be helpful for data mediation. Moreover, a 
structured knowledge space would produce grid services for indexing of distributed 
data resources and thus improve navigation through knowledge and retrieval of 
relevant information. 
Finally, present and future in silico information must be supported and 
validated by data gathered in vitro and in vivo.  The challenges in this domain remain 
severe.  Difficulties of cloning and expressing parasite proteins in heterologous 
systems, the validation of druggable targets using siRNA etc, and the experimental 
assignment of functionality to the many hypothetical proteins, will occupy scientists 
in parallel for some time to come. Data generated from in silico analysis leads to a 
need for further laboratory work, such as the in vitro testing of ligands identified as 
potential drug leads through the WISDOM project. A strong linkage between 
scientists undertaking in vitro research and in silico researchers is therefore essential 
to support an iterative approach to knowledge generation and analysis, in the context 
of malaria chemogenomics. 
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Figures 
Figure 1  - Malaria functional genomics (X-omics) strategies in the context of 
target and drug characterization 
Selected questions that could be addressed by the application of functional genomics 
are listed, including those specific to the transcriptome, proteome or interactome (X-
omes). Highlighted is the particular focus on the application of this type of strategies 
to drug(s) and target(s) characterization. 
Figure 2  - Current pipeline for the homology-based modeling of malaria 
protein 3D-structures 
This scheme emphasizes on the currently available methods to overcome amino acid 
bias, low sequence identity, protein inserts etc. Future upgrades include the 
refinement of each of these methods, for instance implementing asymmetric 
substitution matrices discussed in the text, that take into account the different amino 
acid distributions of malarial and non-malarial proteins for pairwise alignments. 
Figure 3  - In silico screening for protein ligands based on structural docking 
A urea analogue inhibiting malaria plasmepsins was identified with good score from 
the first WISDOM (World-wide In Silico Docking On Malaria) campaign. The 
WISDOM initiative successfully deployed large scale in silico docking on the 
European public EGEE grid infrastructure. The ligand shown here docks inside the 
binding pocket of plasmepsin, and interacts with key protein residues. The developed 
and established protocols can be used for new targets, and particularly a second 
computing challenge, WISDOM II. 
Figure 4  - Malaria chemogenomics: organization and treatment of genomic, 
post-genomic and chemical information for the prediction and characterization 
of target and drug candidates 
Genomic data from Plasmodium and other species (a), i.e. protein sequences, should 
be organized based on sequence similarity (b). This projection should allow the high 
throughput reconstruction of molecular phylogenies both at the intraspecific 
(connecting paralogs and alleles) and interspecific (connecting homologues among 
which orthologs) levels following statistically accurate methods e.g. the TULIP 
method. Another substantial side of the biological space is designed by representing 
our knowledge of the biological processes, using stable ontologies e.g. the GO, and 
dynamic graph representation, e.g. PlasmoCyc (c). Versatile tools should allow the 
integration of genomic data, biological process representations and global functional 
profiles obtained with diverse X-omic approaches (4). These tools should comply 
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with the large diversity of technologies and mining methods. The collection of 
information on the biological response to drugs is one of the doors to connect the 
biological space with the chemical space, following the "reverse chemical genetic" 
way, i.e. "from known drugs to biological response" (toxicity, mode of action). The 
other door to connect the chemical space and the biological space follows the "direct 
chemical genetic" way, i.e. "from known biological target to drug candidates". In 
addition to malaria protein structures obtained from crystals, the automated structural 
annotation of the malaria proteome should be initiated with quality scores (e). Based 
on protein structure information, virtual docking campaigns such as the WISDOM 
challenges can be achieved using the power of computer grids. The in silico 
organization of the small molecules stored in chemolibraries (f) follows similar 
principles, in particular the determination of three-dimensional structures of small 
molecules (g) and a clustering of small molecular structures based on drug properties 
and descriptors (h). Sharing and mining of chemogenomic information, completed 
with knowledge harvested in unstructured scientific literature, would benefit of the 
advances in knowledge space design and deployment on knowledge grids.  
Tables 
Table 1  - Comparison of Plasmodium falciparum, Saccharomyces cerevisiae, 
Arabidopsis thaliana and Homo sapiens genomic statistics 
Presented data compile information from [22] for Plasmodium falciparum, [190] for 
yeast (completed with statistics made available via the Comprehensive Yeast Genome 
Database website, [191]), the Arabidopsis genome initiative [192] for Arabidopsis, 
and the International Human Genome Sequencing Consortium [193] and [194] for 
Human (completed with statistics made available via Ensembl, [195]). These statistics 
at the complete genome release date have been continuously updated since then.  
Table 2  - Non-redundant malarial structures in the Protein Data Bank (PDB). 
All entries were compiled from the PDB, and were cross-checked against PlasmoDB 
([196], versions 4 and 5), the Structural Genomics Consortium, [145] and the 
Structural Genomics of Pathogenic Protozoa, [146]). P. b., Plasmodium berghei; P. c., 
Plasmodium cynomolgi; P.f., Plasmodium falciparum, P. k., Plasmodium knowlesii; 
P. m., Plasmodium malariae, P. v., Plasmodium vivax 
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 Plasmodium 
falciparum 
Saccharomyces 
cerevisiae 
Arabidopsis 
thaliana 
Homo sapiens
Genome general statistics 
No of chromosomes 14 16 5 22 + X/Y 
Size (bp) 22,853,764 12,495,682 115,409,949 3,272,187,692
average (A+T) % 80.6 61.7 65.1 59.0 
Estimated number of genes 5,268 5,770 25,498 31,778 
Average gene length 2,283 1,424 1,310 1,340 
% of coding genome 53 66 29 9 
Initial annotation based on sequence similarity (BLAST or *Smith-Waterman E-values) 
Proportion of predicted protein sequences: 
- having a detectable similarity to sequences, 
in other organisms, of known function at the 
initial genome release date. 
34 % 75 % 69 % 59 %* 
- without any detectable similarity to 
sequences in other organisms at the initial 
genome release date, i.e. "no BLASTP match 
to known proteins" (estimates based on 
published data and local BLAST searches). 
61 % < 8 % < 20 % 15 %* 
- of totally unknown function (hypothetical 
proteins = with similarity to sequences of 
unknown function + without any detectable 
similarity to sequences in other organisms). 
66 % 16 % 31 % 41 %* 
Average characteristics of open reading frames 
Exons:     
No per gene 2.39 1.05 5.18 12.1 
 (A+T) % 76.3 60 55 52 
average length 949 1356 253 111 
Introns:     
(A+T) % 86.5 64 66 60 
Intergenic regions:     
 (A+T) % 86.4 64 66 60 
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Description PDB Ids Ligands Species 
1-Cys peroxiredoxin 1XIY, 1XCC  P. f., P. y. 
2-Cys peroxiredoxin 2H66, 2FEG  P. v. 
6-pyruvoyl tetrahydropterin 
synthase 
1Y13, 2AOS Biopterin P. f., P. v. 
Acyl CoA binding protein 1HBK  P. f. 
Adenylosuccinate synthetase 1P98  P. f. 
Adenylosuccinate lyase 2HVG  P. v. 
Apical membrane antigen 1 1HN6, 1Z40, 1W81, 1W8K  P. f., P. v. 
beta-hydroxyacyl-ACP 
dehydratase 
1Z6B, 1ZHG Cacodylate P. f. 
Cell division control protein 2 
homolog, Pfpk5 
1V0P, 1VOB, 1V0O, 1OB3 Purvalanol B, Indirubin-5-Sulphonate P. f. 
ClpP protease 2F6I  P. f. 
C-terminal merozoite surface 
protein 
1B9W  P. c. 
cyclophilin, peptidyl-prolyl 
cis-trans isomerase 
1QNH, 1QNG, 1Z81, 2B71, 
2FU0 
Cyclosporin A P. f., P. y. 
DHFR-TS 1J3J, 1J3I, 1J3K, 2BL9, 
2BLB 
Pyrimethamine, NADPH , dUMP, 
WR99210, NDP, CP6, MES, CP7 
P. f., P. v. 
Dihydroorotate 
dehydrogenase 
1TV5 orotic acid, n8e, fmn, a26 P. f. 
Dimethyladenosine 
transferase 
2H1R  P. f. 
dUTPase 1VYQ 2 ,3-deoxy-3-fluoro-5-o-trityluridine P. f. 
Dynein Light Chain 1 1YO3  P. f. 
Enoyl-acyl-carrier protein 
reductase 
1NHG, 1NHW, 1NHD/ 
1VRW, 1NNU 
Triclosan, NAD+, TCC, TCT P. f. 
Falcipain-2 1YVB, 2GHU  P. f. 
Ferredoxin 1IUE  P. f. 
Fe-superoxide dismutase 2AWP, 2A03  P. k., P. b. 
Fructose-bisphosphate 
aldolase 
1A5C  P. f. 
Glutamate dehydrogenase 2BMA  P. f. 
Glutathione reductase 1ONF  P. f. 
Glutathione S-transferase 1PA3, 1Q4J, 1OKT, 2AAW S-Hexyl-Gsh, P33, GTX, DTL P. f. 
Glyceraldehyde-3-phosphate 
dehydrogenase 
1YWG, 2B4R, 2B4T NAD+, glycerol, AES P. f. 
Glycerol-3-phosphate 
dehydrogenase 
1YJ8  P. f. 
Guanylate kinase 1Z6G 4-(2-hydroxyethyl)-1-piperazine 
ethanesulfonic acid 
P. f. 
Hypothetical protein 1ZSO  P. f. 
Hypoxanthine 
phosphoribosyl-transferase 
1CJB  P. f. 
L-lactate dehydrogenase 1LDG, 1CET, 1CEQ, 1T26, 
1T2E, 1T25, 1T24, 1T2D, 
1T2C, 1U4O, 1U5S, 1U5C, 
1U5A, 1XIV, 2A94, 1OC4, 
2A92, 2AA3 
NADH,Oxamate, Chloroquine, 4-
Hydroxy-1,2,5-Thiadiazole-3-
Carboxylic Acid, 3-Hydroxyisoxazole-
4-Carboxylic Acid, NAD+, 4-Hydroxy-
1,2,5-Oxadiazole-3-Carboxylic Acid, 
2,6-dicarboxynaphthalene, naphthalene-
2,6-disulfonic acid, 3,7-
dihydroxynaphthalene-2-carboxylic 
acid, RB2, glycerol, Acetyl pyridine 
adenine dinucleotide, 1,4-
dihydronicotinamide adenine 
dinucleotide, ADAPH 
P. f., P. b., 
P. v. 
MDR 2 2GHI  P. y. 
MSP1 1OB1, 2FLG, 1CEJ, 1N1I  P. f., P. k. 
MSP3 1PSM  P. f. 
MTIP-MyoA complex 2AUC  P. k. 
Nucleoside diphosphate 
kinase B 
1XIQ  P. f. 
Ornithine aminotransferase 1Z7D  P. y. 
Oxoacyl-ACP reductase 2C07  P. f. 
Phosphatidylethanolamine- 2GZQ  P. v. 
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binding protein 
Phosphoglycerate kinase 1LTK  P. f. 
Phosphoglycerate mutase 1XQ9 SCN P. f. 
Plasmepsin 1LS5, 1SME, 1ME6, 1LF2, 
1LF4, 1PFZ, 1LEE, 1LF3, 
1M43, 1MIQ, 2ANL, 
1QS8, 1W6H, 1W6I, 2BJU, 
1XE5, 1XE6, 1XDH 
Peptstatin A, Inhibitor Rs370, Statine 
analogue, Inhibitor Rs367, Inhibitor 
Eh58, JE2 
P. f., P. v., 
P. m. 
P. f. gamete antigen 27/25 1N81  P. f. 
Purine nucleoside 
phosphorylase 
2BSX Inosine P. f. 
Putative adenosine deaminase 2AMX  P. y. 
Putative deoxyribose-
phosphate aldolase 
2A4A  P. y. 
Putative, dim1 protein 
homolog 
2AV4  P. y. 
putative FK506-binding 
protein PFL2275c 
2FBN  P. f. 
Putative formylmethionine 
deformylase 
1JYM, 1RQC, 1RL4 BRR, BL5 P. f. 
putative HAD/COF-like 
hydrolase 
2B30  P. v. 
Putative, heat shock protein 1Y6Z  P. f. 
Putative, histamine-releasing 
factor 
1TXJ  P. k. 
Putative, orotidine-
monophosphate-
decarboxylase 
2AQW, 2FDS, 2GUU, 
2FFC, UP6 
Sulphate, SeMethionine, Uridine-5'-
monophosphate 
P. y., P. b., 
P. v. 
Putative uridine 
phosphorylase 
1Q1G, 1SQ6, 1NW4 5'- Methylthio-Immucillin-H, Immh P. f. 
Putative, vacuolar protein 
sorting 29 
2BDD  P. y. 
Pvs25 1Z1Y, 1Z27  P. v. 
Rab6 1D5C GDP P. f. 
Ribose 5-phosphate isomerase 2F8M Phosphate P. f. 
Ribulose 5-phosphate 3-
Epimerase 
1TQX  P. f. 
Spermidine synthase 2FEG MTA P. f. 
Thioredoxin 1SYR, 2AV4  P. f., P. y. 
Thioredoxin peroxidase I 2H01  P. y. 
Triose Phosphate Isomerase 1LYX, 1LZO, 1M7O, 
1O5X, 1VGA, 1WOA, 
1WOB, 1YDV, 1M7P 
2-Phosphoglycolic acid, Glycerol-3-
Phosphate, 2-Phosphoglycolic acid, 3-
Phosphoglyceric acid, 2-
phosphoglycerate 
P. f. 
Ubiquitin conjugating enzyme 
E2 
2H2Y, 2FO3  P. f., P. v. 
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